Deals
Biotie Jumps Most in Seven Weeks on Drug Plans: Helsinki Mover
This article is for subscribers only.
Biotie Therapies Oyj, the drugmaker that developed an anti-alcoholism drug with H. Lundbeck A/S, rose the most in more than seven weeks after announcing the results of a review to maximize value from its products.
The shares rose as much as 5.9 percent, the biggest jump since Aug. 5. The stock was up 2.9 percent at 35 euro cents as of 1:31 p.m. in the Finnish capital. The volume of shares traded was more than three times the three-month daily average.